Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04748107

Treatment of Severe Hypertension With ICG Directed Therapy

Hypertension in Pregnancy Clinical Trial

Official title:
Treatment of Severe Hypertension With Impendence Cardiography (ICG) Directed Therapy; a Randomized Controlled Trial

Clinical Trial Summary

The purpose of the study is to compare the usefulness of Impedence Cardiography (ICG) directed therapy in treating severe range hypertension in pregnant women at term.

Clinical Trial Description

Research Protocol Study Design: Randomized Control Trial This is a randomized control trial comparing the usefulness of impedance cardiography (ICG) directed therapy in treating severe range hypertension (systolic BP >160 OR diastolic BP >110) in patients greater than 20 weeks gestation. All patients in the study will receive standard of care medication within the suggested timeframe by the American College of Obstetrics and Gynecology (ACOG). All patients will receive a hemodynamic assessment prior to receiving and after receiving medications. The treatment patients will receive either labetalol or nifedipine therapy for hypertension based on their hemodynamic parameters. The control group will receive medication based on provider preference (which is the usual plan of care). Study Population: Patients presenting to Labor and Delivery at Cabell Huntington Hospital being treated for severe range blood pressures. Consent will be obtained prior to randomization to standard care or ICG directed care. Patient age range will be from age 15 to approximately 45. Schedule of Assessment: An interval assessment will be performed after 20 patients have been assessed. The goal is for a total enrollment of 100 patients, 50 to the ICG directed treatment group and 50 to the control group. Study Procedures: If a patient presents to Labor and Delivery at Cabell Huntington Hospital and consents to the study, she will be randomized to either the ICG directed therapy group or provider preference group. Patients from each group will receive a non-invasive hemodynamic assessment via the NICaS system. The NICaS system uses impedance cardiography which provides a reliable assessment of cardiovascular, respiratory, and fluid parameters. The vasodilator nifedipine will be initiated for increased systemic vascular resistance. Elevated cardiac output will be treated with beta blockade via IV labetalol. ACOG recommends either of these medications as first line therapy for elevated blood pressure, and offers no guidance on which medication should be used first. All patients who are being treated will receive the standard of care treatment, however the ICG group will receive therapy based on their hemodynamic parameters. Study Analysis The control group will be compared to the ICG directed treatment group. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04748107
Study type Interventional
Source Marshall University
Contact
Status Withdrawn
Phase N/A
Start date April 25, 2021
Completion date June 1, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT00974714 - L-arginine Effects on Chronic Hypertension in Pregnancy Phase 3
Terminated NCT03595982 - Is Procardia XL 60 mg Q Daily Equivalent to 30 mg XL Given Twice Daily? Phase 4
Completed NCT04486170 - Assessment of Postpartum Education to Improve Compliance N/A
Completed NCT03506724 - Response to Anti-hypertensives in Pregnant and Postpartum Patients Phase 4
Completed NCT03613714 - Innovation in Postpartum Care for Women With Hypertensive Disorders of Pregnancy N/A
Recruiting NCT04604535 - The BEET-BP Trial - Investigating the Effect of Dietary Nitrates on Hypertension in Pregnancy N/A
Completed NCT00412230 - Insulin Resistance and Hypertensive Disorders in Pregnancy N/A
Active, not recruiting NCT05049616 - Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension Phase 4
Completed NCT04119232 - Randomized Clinical Trial to Increase Physical Activity After a a Hypertensive Pregnancy N/A
Completed NCT04633551 - Vascular Inflammation and Anti-inflammatory Supplements After Adverse Pregnancy Outcomes N/A
Completed NCT05859282 - Development and Validation of a Short Tool to Assess the Awareness of Pregnancy-induced Hypertension
Active, not recruiting NCT05543265 - Bridging the Gap From Postpartum to Primary Care N/A
Completed NCT00571766 - Effects of Oral L-Arginine on Chronic Hypertension in Pregnancy Phase 3
Recruiting NCT05473767 - Expanding the Family Check-Up in Early Childhood to Promote Cardiovascular Health of Mothers and Young Children N/A
Recruiting NCT05683093 - Cardiovascular Longitudinal ALSPAC Research Investigations Following Hypertensive Pregnancy in Young Adulthood
Recruiting NCT05852054 - Supporting Transitions to Primary Care Among Under-resourced, Postpartum Women (STEP-UP) Phase 3
Recruiting NCT05137808 - Understanding Blood Pressure Changes After Birth
Active, not recruiting NCT03961360 - Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida Phase 2/Phase 3
Active, not recruiting NCT03648645 - Hypertensive Pregnant Women Monitored by Teletransmitted Self-measurements of Blood Pressure N/A
Recruiting NCT06054841 - Reshaping Postpartum Follow-up N/A